Bridgewater Associates LP Decreases Stock Holdings in Insulet Co. (NASDAQ:PODD)

Bridgewater Associates LP lessened its position in shares of Insulet Co. (NASDAQ:PODD) by 22.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 11,142 shares of the medical instruments supplier’s stock after selling 3,270 shares during the period. Bridgewater Associates LP’s holdings in Insulet were worth $2,593,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Insulet during the second quarter worth about $32,000. Venturi Wealth Management LLC increased its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. raised its position in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Finally, CVA Family Office LLC boosted its stake in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 145 shares in the last quarter.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $266.78 on Friday. The company has a market capitalization of $18.71 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company’s fifty day moving average price is $244.40 and its 200 day moving average price is $213.85. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.40.

Analyst Ratings Changes

Several equities research analysts have recently commented on PODD shares. Canaccord Genuity Group lifted their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler lifted their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Finally, UBS Group increased their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.